Janux Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 63.06 million compared to USD 32.67 million a year ago. Basic loss per share from continuing operations was USD 1.52 compared to USD 1.39 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.96 USD | +1.64% | -2.48% | +281.73% |
06-06 | Janux Therapeutics Insider Sold Shares Worth $45,043,975, According to a Recent SEC Filing | MT |
06-06 | Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+281.73% | 2.12B | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- JANX Stock
- News Janux Therapeutics, Inc.
- Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022